Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seratrodast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 5/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CDC25A | P30304 | 2/20 | 0.40 |
| ▸ | CDC25B | P30305 | 2/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seratrodast SCHEMBL98402 | 1.00 | TBXAS1 (0.52) | TBXAS1TBXA2RMAPTRXFP1HDAC3 | |
| SCHEMBL9308117 | 1.00 | TBXAS1 (0.52) | TBXAS1TBXA2RMAPTRXFP1HDAC3 | |
| SCHEMBL9308585 | 0.99 | TBXAS1 (0.50) | TBXAS1TBXA2RMAPTRXFP1HDAC3 | |
| SCHEMBL2459057 | 0.90 | TBXAS1 (0.42) | TBXAS1TBXA2RHDAC3HDAC1HDAC2 | |
| SCHEMBL7832557 | 0.90 | TBXAS1 (0.51) | TBXAS1TBXA2RMAPTRXFP1HDAC3 | |
| SCHEMBL2490724 | 0.90 | TBXA2R (0.46) | TBXAS1TBXA2R | |
| SCHEMBL7812983 | 0.88 | CDC25B (0.43) | TBXAS1TBXA2RRXFP1CDC25ACDC25B | |
| SCHEMBL9309433 | 0.88 | TBXA2R (0.44) | TBXAS1TBXA2RALDH1A1 | |
| SCHEMBL2458688 | 0.88 | TBXA2R (0.59) | TBXAS1TBXA2R | |
| SCHEMBL7833657 | 0.87 | HDAC1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3159 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025184468-A9 | MEASUREMENT OF URINE THROMBOXANE METABOLITES TO PREDICT SURVIVAL | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250144079-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2025-05-08 | — | — | US | claimed |
| EP-1962797-B2 | POWDER COMPOSITIONS FOR INHALATION | JAGOTEC AG (CH) | 2024-05-29 | — | — | EP | claimed |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-11667707-B2 | SPNS2 neutralizing antibody | TEIJIN PHARMA LIMITED (JP) | 2023-06-06 | — | — | US | claimed |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2023-03-23 | — | — | US | claimed |
| CN-111405895-B | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114848619-A | Application of seratrodast in preparation of medicines for preventing and treating iron death related diseases | 广州医科大学 | 2022-08-05 | — | — | CN | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| EP-1131059-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2001-09-12 | — | — | EP | claimed |
| US-6284790-B1 | ADMINISTERING A THROMBOXANE RECEPTOR ANTAGONIST AND A REDUCING AGENT. | GUPTE SACHIN (US) | 2001-09-04 | — | — | US | claimed |
| WO-2001012584-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2001-02-22 | — | — | WO | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000061537-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000028979-A1 | DRY POWDER FOR INHALATION | JAGO RESEARCH AG (CH) | 2000-05-25 | — | — | WO | claimed |
| US-6020380-A | RESPIRATORY SYSTEM DISORDERS; ADMINISTERING7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYL HEPTANOIC ACID | TAP HOLDINGS INC. (US) | 2000-02-01 | — | — | US | claimed |
| US-5830432-A | Phospholipid drug derivatives | AMUR PHARMACUTICALS, INC. (US) | 1998-11-03 | — | — | US | claimed |
| WO-1998043676-A1 | PHOSPHOLIPID DRUG DERIVATIVES | AMUR PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | claimed |
| WO-1998022114-A1 | A METHOD FOR PROMOTING TISSUE REPAIR | DUMEX-ALPHARMA A/S (DK) | 1998-05-28 | — | — | WO | claimed |